EIKANCE (Aspen Pharmacare Australia Pty Ltd)
Product name
EIKANCE
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
atropine sulfate monohydrate
Registration type
EOI
Indication
EIKANCE (0.01% eye drop solution) is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 D per year.